Cantor Fitzgerald L. P. Buys New Holdings in Eli Lilly and Company (NYSE:LLY)

Cantor Fitzgerald L. P. acquired a new stake in Eli Lilly and Company (NYSE:LLY - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 4,546 shares of the company's stock, valued at approximately $3,510,000.

Other institutional investors also recently bought and sold shares of the company. Principal Financial Group Inc. increased its position in shares of Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company's stock valued at $1,070,698,000 after buying an additional 60,306 shares in the last quarter. Nordea Investment Management AB raised its position in Eli Lilly and Company by 13.7% during the fourth quarter. Nordea Investment Management AB now owns 1,154,350 shares of the company's stock worth $887,014,000 after acquiring an additional 138,835 shares during the period. Legacy Wealth Management LLC MS purchased a new position in Eli Lilly and Company during the fourth quarter valued at $215,000. CWA Asset Management Group LLC grew its position in shares of Eli Lilly and Company by 11.9% in the fourth quarter. CWA Asset Management Group LLC now owns 6,794 shares of the company's stock valued at $5,245,000 after purchasing an additional 724 shares during the period. Finally, Neville Rodie & Shaw Inc. increased its stake in shares of Eli Lilly and Company by 0.6% during the fourth quarter. Neville Rodie & Shaw Inc. now owns 15,031 shares of the company's stock worth $11,604,000 after purchasing an additional 97 shares in the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.14% of the stock is owned by insiders.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and reduced their target price for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. UBS Group dropped their price objective on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating for the company in a research note on Friday. Citigroup lowered their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating on the stock in a report on Tuesday, January 28th. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Eli Lilly and Company in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, two have given a hold rating and nineteen have assigned a buy rating to the company's stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of "Moderate Buy" and a consensus target price of $1,002.80.

Eli Lilly and Company Price Performance

Shares of LLY traded down $45.20 during trading hours on Tuesday, reaching $776.26. The company had a trading volume of 5,961,205 shares, compared to its average volume of 3,485,580. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $735.69 billion, a price-to-earnings ratio of 66.29, a PEG ratio of 1.40 and a beta of 0.48. The firm has a 50 day simple moving average of $820.91 and a 200-day simple moving average of $814.03.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion during the quarter, compared to analysts' expectations of $12.77 billion. During the same quarter in the prior year, the business earned $2.58 EPS. The company's quarterly revenue was up 45.2% compared to the same quarter last year. Research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a $1.50 dividend. This represents a $6.00 dividend on an annualized basis and a yield of 0.77%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is currently 48.82%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.